Gender specific responses in platelet function following long chain omega-3 fatty acid supplementation

Supplementation with long chain omega-3 polyunsaturated fatty acids to reduce platelet aggregation differentially by gender in healthy volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000164291

Enrollment

Registered

2009-04-03

Start date

2009-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of this study is to determine the gender specific responses in platelet reactivity following supplementation with long chain omega-3 polyunsaturated fatty acids (LCn-3 PUFA). It is anticipated that there will be significant gender related differences in response to different concentration ratios of long chain n-3 PUFA supplementation. This research study is designed to assess the effectiveness of Eicosapentaenoic Acid and Docoshexaenoic Acid to inhibit platelet aggregation in healthy males versus females. These studies will be randomised controlled trials where platelet function of healthy subjects will be monitored over the intervention period following dietary supplementation of the fish oil concentrates or placebo.

Interventions

Participants of equal gender are randomised to receive an oral administration of a single dose of either omega-3 fish oil capsules or placebo containing: (i) 2 x 1g dose 500mg Docosahexaenoic Acid (DHA) [1:5 EPA/DHA] (ii) 2 x 1g dose 500mg Eicosapentaenoic Acid [5:1 EPA/DHA] (iii) 2 x 1g dose Placebo (olive oil) Participants are assessed at baseline and at post 2, 5 and 24 hours following consumption of the capsules.

Study design

Allocation

Randomised controlled trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

Healthy participants aged 25 years or above.

Exclusion criteria

Participants diagnosed with any hematological or cardiovascular disorders and are taking fish oil capsules or medication affecting coagulation.

Outcome results